FPR1 and arthritic joint disease: Pre-treatment of the animals with FPR antagonists (Boc-MLF and WRW4) resulted in complete reversal of the effects of Cpd43, thus demonstrating the direct correlation between FPR activation by Cpd43 and reduction of arthritis severity.